Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Schwab now offering 8% interest for AUPH share lending (up from 5%)
If you're interested and have the time, this is a nice article summarizing the current state of affairs in dry eye disease research, including some good information on the development pathway of cyclosporin for dry eyes (first developed in dogs):
Scientific backgrounder on dry eye disease
Thank you, that's very helpful information.
If you agree to the plan, is the rate locked or does it float?
I have just received an email from Charles Schwab asking me to make my AUPH shares available to be lent out. Ha!
I bought some more EXEL late yesterday, ARRY too
So I'm in a departure lounge at DFW waiting to board a flight to YVR (for business unrelated to my investments) and I find myself disproportionately happy to be going on this trip.
I will be keeping my eyes and ears open for pharma execs in Vancouver ;)
MMs enjoying a well earned siesta. They will be back at their desks shortly
I love the timing of the PR last night. Nobody was expecting any news until market close today. Caught the market, and especially the shorts off guard, in the best possible way.
"Are we likely to repeat the 60 point game in P3?"
p values matter, and the ones in AURA LV were stellar
48 wk CR: Low dose VOC 49%. vs 24% in control arm p<0.001
It is a difficult arena, nobody is arguing that point. Go back to Dr. Parikh's slide with the tombstones of 8 drugs for LN.
That's what makes the AURA LV results so exciting. And AURORA is just a repeat (hopefully without the deaths...)
Strong numbers there, better than anticipated.
Seems like something's up, eh?
What is happening!? I don't understand how/why they would PR this!
Post it in the break room, maybe.
From your lips to God's ears
I think the catch is safety. It sounds plausible that the deaths in Ph 2 voclosporin patients were not due to the drug but to other factors.
Since they are accounting for those other factors in the Ph 3 trial, we should be golden (and I believe we are).
But if we are wrong on the cause of the deaths and they happen again in AURORA, this company is DEAD. Crazier things have happened and we are not truly out of the woods until the Ph 3 data are in hand.
Please let the buyout come before then!
Exactly! Can't wait for the stock to start closing at 6.66, lol.
Thanks for that, the name didn't click with me and I had been meaning to relisten and look that up
Great! Good luck to us both with AUPH!
I agree with what you and others are saying about diversification, but I would caution you against having 75% of your portfolio in a single security, especially a small cap bio.
AUPH is great, one of the best investment opportunities that I have seen. I have taken an outsize position in this company. It represents 10% of my portfolio.
Look at 3 year charts on CLDX, TTPH, ECYT, CEMP. Once promising companies, all.
"Both patients had significant disease regression and symptomatic improvement for over 15 months with tolerable adverse effects,” reported the authors.
Because ophthalmics is not my strong suit and I have this unbearably long 2.5 yr wait ahead of me ;) I thought that I would look for some reading material to educate myself on nanomicelles. I found this article helpful, maybe you will too:
Nanomicelles
Then don't... ;)
The Ph3 trial has not started yet (expected to start this quarter). If patient enrollment is brisk, expect top line results in 2.5 yrs. Clinicaltrials.gov gives an expected completion date of March 2020.
https://clinicaltrials.gov/ct2/show/NCT03021499?term=voclosporin&rank=4
Guess where some of the best mountain biking in the world can be found...
British Columbia!
Ah, the Bay area! Love it!
I grew up riding my mountain bike in the hills around Lafayette (East Bay).
Now I live in Dallas where we call it "off road bicycling"
I also just turned 40 but have been investing for some time.
My first investment was in AirTouch Communications in Dec 1998. The company was acquired by Vodafone less than a month later for a substantial premium! What a feeling! But I will say that "Hey, this is easy" is exactly the wrong lesson for a new investor. Naturally I got my a$$ handed to me in 2000 (and several times since).
Pet peeve: I've seen this in several places and Cantor has now committed the same sin:
AURA LV was not VOC vs placebo. It was VOC+MMF+Steroids vs Placebo+MMF+Steroids.
It has an active control arm which makes the results that much more compelling?. This is crucial.
I worry that when it is reported as VOC vs placebo, that people will look at AURORA (which has the same active control arm) and question unnecessarily whether they will be able to replicate the results.
/rant
If by "slow" you mean 2-3 yrs for a 6-10x gain, then I'll take it. Is there some better deal out there than that?
Generally agree, but I would refine it one step further:
A great product is necessary, but not sufficient for success. You need a CEO who is ready, willing and able to do battle for the company.
Such a CEO without a solid product is a snake oil salesman...
Fortunately for us and for people suffering from LN, AUPH has both.
I also sold half of ARIA stake on news and let the other half ride.
Not only does this company have a great drug that is going to help many patients, but they have a CEO who knows how to play the game. That's a winning combination right there
Buy low, sell high (not the reverse)
Seems like responsible cash management and projects confidence about future revenue. I like it too
Confirmed on Congress schedule. Presentation at about 6 pm Melbourne time, 3 AM in NY.
What's the plan, folks? Buy Friday, sell the news on Monday?
Tacrolimus, rituximab and abatacept have all been studied in LN in the last several years. Maybe you were thinking of one of those?
Yeah, I'm still holding a small position in ARRY (1/10th of my ARIA profits). Not fun, but I don't think the drug is dead... But they are set back a year now.